SGMO
Income statement / Annual
Last year (2024), Sangamo Therapeutics, Inc.'s total revenue was $57.80 M,
a decrease of 67.20% from the previous year.
In 2024, Sangamo Therapeutics, Inc.'s net income was -$97.94 M.
See Sangamo Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$57.80 M |
$176.23 M |
$111.30 M |
$110.70 M |
$118.19 M |
$102.43 M |
$84.45 M |
$36.57 M |
$19.39 M |
$39.54 M |
| Cost of Revenue |
$0.00
|
$221.56 M
|
$12.11 M
|
$9.44 M
|
$180.65 M
|
$145.92 M
|
$114.87 M
|
$65.73 M
|
$65.62 M
|
$67.13 M
|
| Gross Profit |
$57.80 M
|
-$45.33 M
|
$99.19 M
|
$101.26 M
|
-$62.46 M
|
-$43.49 M
|
-$30.41 M
|
-$29.16 M
|
-$46.23 M
|
-$27.59 M
|
| Gross Profit Ratio |
1
|
-0.26
|
0.89
|
0.92
|
-0.53
|
-0.42
|
-0.36
|
-0.8
|
-2.38
|
-0.7
|
| Research and Development Expenses |
$111.52 M
|
$234.06 M
|
$249.90 M
|
$230.82 M
|
$180.65 M
|
$145.92 M
|
$114.87 M
|
$65.73 M
|
$65.62 M
|
$67.20 M
|
| General & Administrative Expenses |
$44.73 M
|
$61.17 M
|
$62.68 M
|
$63.22 M
|
$67.10 M
|
$61.69 M
|
$46.74 M
|
$27.20 M
|
$26.33 M
|
$19.20 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$44.73 M
|
$61.17 M
|
$62.68 M
|
$63.22 M
|
$67.10 M
|
$61.69 M
|
$46.74 M
|
$27.20 M
|
$26.33 M
|
$19.20 M
|
| Other Expenses |
$5.52 M
|
$155.01 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$887,000.00
|
$431,000.00
|
| Operating Expenses |
$161.77 M
|
$450.24 M
|
$312.58 M
|
$294.04 M
|
$247.74 M
|
$207.61 M
|
$161.60 M
|
$92.93 M
|
$91.95 M
|
$86.40 M
|
| Cost And Expenses |
$161.77 M
|
$450.24 M
|
$312.58 M
|
$294.04 M
|
$247.74 M
|
$207.61 M
|
$161.60 M
|
$92.93 M
|
$91.95 M
|
$86.40 M
|
| Interest Income |
$5.86 M
|
$11.10 M
|
$9.43 M
|
$5.35 M
|
$8.78 M
|
$9.76 M
|
$8.26 M
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$9.36 M
|
$22.19 M
|
$12.11 M
|
$9.44 M
|
$5.68 M
|
$3.93 M
|
$2.36 M
|
$1.50 M
|
$997,000.00
|
$988,000.00
|
| EBITDA |
-$89.09 M |
-$87.43 M |
-$189.17 M |
-$173.90 M |
-$123.87 M |
-$101.25 M |
-$74.79 M |
-$54.86 M |
-$70.68 M |
-$45.80 M |
| EBITDA Ratio |
-1.54
|
-0.5
|
-1.7
|
-1.66
|
-1.1
|
-1.03
|
-0.91
|
-1.54
|
-3.74
|
-1.19
|
| Operating Income Ratio |
-1.8
|
-1.55
|
-1.81
|
-1.66
|
-1.1
|
-1.03
|
-0.91
|
-1.54
|
-3.74
|
-1.19
|
| Total Other Income/Expenses Net |
$5.86 M
|
$11.10 M
|
$9.43 M
|
$5.35 M
|
$8.78 M
|
$9.76 M
|
$8.26 M
|
$1.79 M
|
$887,000.00
|
$431,000.00
|
| Income Before Tax |
-$98.11 M
|
-$262.90 M
|
-$191.85 M
|
-$177.99 M
|
-$120.78 M
|
-$95.42 M
|
-$68.89 M
|
-$54.57 M
|
-$71.67 M
|
-$46.43 M
|
| Income Before Tax Ratio |
-1.7
|
-1.49
|
-1.72
|
-1.61
|
-1.02
|
-0.93
|
-0.82
|
-1.49
|
-3.7
|
-1.17
|
| Income Tax Expense |
-$167,000.00
|
-$5.07 M
|
$429,000.00
|
$306,000.00
|
$345,000.00
|
-$19.60 M
|
$8.26 M
|
-$1.50 M
|
-$14,000.00
|
-$5.72 M
|
| Net Income |
-$97.94 M
|
-$257.83 M
|
-$192.28 M
|
-$178.30 M
|
-$121.12 M
|
-$75.82 M
|
-$68.33 M
|
-$54.57 M
|
-$71.66 M
|
-$40.70 M
|
| Net Income Ratio |
-1.69
|
-1.46
|
-1.73
|
-1.61
|
-1.02
|
-0.74
|
-0.81
|
-1.49
|
-3.7
|
-1.03
|
| EPS |
-0.49 |
-1.48 |
-1.25 |
-1.23 |
-0.9 |
-0.68 |
-0.7 |
-0.7 |
-1.02 |
-0.58 |
| EPS Diluted |
-0.49 |
-1.48 |
-1.25 |
-1.23 |
-0.9 |
-0.68 |
-0.7 |
-0.7 |
-1.02 |
-0.58 |
| Weighted Average Shares Out |
$201.70 M
|
$174.44 M
|
$154.35 M
|
$144.57 M
|
$134.45 M
|
$112.11 M
|
$96.94 M
|
$78.08 M
|
$70.55 M
|
$69.76 M
|
| Weighted Average Shares Out Diluted |
$201.70 M
|
$174.44 M
|
$154.35 M
|
$144.57 M
|
$134.45 M
|
$112.11 M
|
$96.94 M
|
$78.08 M
|
$70.55 M
|
$69.76 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
